Search | WHO COVID-19 Research Database

A Real-World Evidence Framework for Optimizing Dosing in All Patients With COVID-19.

Peck, Richard W; Weiner, Daniel; Cook, Jack; Robert Powell, J.

Clin Pharmacol Ther ; 108(5): 921-923, 2020 11.

Article in English | MEDLINE | ID: covidwho-878708

ABSTRACT

Potential treatments for coronavirus disease 2019 (COVID-19) are being investigated at unprecedented speed, and successful treatments will rapidly be used in tens or hundreds of thousands of patients. To ensure safe and effective use in all those patents it is essential also to develop, at unprecedented speed, a means to provide frequently updated, optimal dosing information for all patient subgroups. Success will require immediate collaboration between drug developers, academics, and regulators.

Subject(s)

Antiviral Agents , Coronavirus Infections , Dose-Response Relationship, Drug , Drug Development , Drug Repositioning , Drug-Related Side Effects and Adverse Reactions , Pandemics , Pneumonia, Viral , Antiviral Agents/pharmacokinetics , Antiviral Agents/therapeutic use , Betacoronavirus/drug effects , Biological Availability , Biomarkers, Pharmacological/analysis , COVID-19 , Coronavirus Infections/drug therapy , Coronavirus Infections/epidemiology , Drug Development/methods , Drug Development/standards , Drug Dosage Calculations , Drug Monitoring/standards , Drug Repositioning/methods , Drug Repositioning/standards , Drug-Related Side Effects and Adverse Reactions/blood , Drug-Related Side Effects and Adverse Reactions/prevention & control , Humans , International Cooperation , Pneumonia, Viral/drug therapy , Pneumonia, Viral/epidemiology , SARS-CoV-2 , Treatment Outcome

ABSTRACT

Subject(s)

SEND TO:

SELECTION OF CITATIONS

SEARCH DETAIL